Nitric oxide inhalation - Novoteris

Drug Profile

Nitric oxide inhalation - Novoteris

Alternative Names: Thiolanox

Latest Information Update: 03 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novoteris
  • Developer Novoteris; University of British Columbia; University of Toronto
  • Class Anti-inflammatories; Antiacnes; Antiandrogens; Antibacterials; Antifibrotics; Antifungals; Antihypertensives; Antivirals; Free radicals; Macromolecular substances; Nitrogen oxides; Non-opioid analgesics; Small molecules; Vasodilators
  • Mechanism of Action Guanylate cyclase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity No

Highest Development Phases

  • Phase II Cystic fibrosis; Mycobacterial infections
  • No development reported Cystic fibrosis-associated respiratory tract infections

Most Recent Events

  • 09 Mar 2018 Phase-II clinical trials in Mycobacterial infections (Treatment-experienced) in Canada (Inhalation) (NCT03473314)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Cystic-fibrosis(In volunteers) in Canada (Inhalation)
  • 31 Oct 2017 Health Canada approves CTA application for Nitric oxide inhalation in Mycobacterial infections (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top